Results Press Release
Pfizer Ltd has submitted to BSE a copy of Results Press Release for the period ended December 31, 2015.03-02-2016
Results Press Release
Pfizer Ltd has submitted to BSE a copy of Results Press Release for the period ended December 31, 2015.Announces Q3 Results (Standalone) & Limited Review Report (Standalone) for the Quarter ended December 31, 2015
Pfizer Ltd has announced the following Un-Audited Standalone results for the quarter ended December 31, 2015 :The Company has posted a net profit of Rs. 403.40 million for the quarter ended December 31, 2015 as compared to Rs. 183.70 million for the quarter ended December 31, 2014. Total Income has increased from Rs. 4914.10 million for the quarter ended December 31, 2014 to Rs. 5300.10 million for the quarter ended December 31, 2015.Pfizer forecasts 2016 revenue, earnings below estimates
Company's net income fell to $613 million, or 10 cents per share in the fourth quarterShareholding for the Period Ended December 31, 2015
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click hereQ3 results on Feb 03, 2016
Pfizer Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 03, 2016, inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2015 (Q3).Further, the Trading Window for trading in the Equity shares of the Company will be closed from January 22, 2016 to February 05, 2016, both days inclusive.Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Pfizer Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Pfizer said to weigh sale of pump unit acquired in Hospira deal
Pfizer could fetch about $2 billion from a potential sale, according to sourcesPfizer goes small for a big brand
Competition and a growing taste for herbal remedies is changing the way the pharma major is positioning one of its bestselling brands, GelusilPfizer hikes US prices for over 100 drugs on 1 January
Prices of some drugs raised by as much as a fifth; list price does not reflect discounts on offerPfizer hikes US prices for over 100 drugs on 1 January
Prices of some drugs raised by as much as a fifth; list price does not reflect discounts on offer